White blood cell count >= 4000 cells/mm^3
285.0
White blood cell count (WBC) >= 4,000/ml
37.0
B-ALL patients must have an initial white blood cell count < 50,000/uL
9483.0
White blood cell (WBC) > 3.0
224.0
White blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) or
90.0
Total white blood cells (WBC) >= 4.0 x 10^3/mcL within 28 days prior to registration
491.0
White blood cells (WBC) >= 3500/uL
92.0
White blood count >= 3,000/uL, obtained within 4 weeks prior to randomization
300.0
White blood count >= 3,000/uL
400.0
Patients with white blood cell (WBC) > 30,000 are not eligible to start therapy; however, it is permissible to use glucocorticoids and/or hydroxyurea to diminish peripheral WBC to less than 30,000 provided these agents are stopped at least 24 hours prior to the first dose of MLN0128 (TAK-228)
35.0
Total absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells [WBC]) is at least 1000/uL
44.0
White blood cell count (WBC) >= 2,000/mcL; must be obtained within 28 days prior to registration
180.0
White blood cell (WBC) >= 2000/uL
714.0
White blood cells >= 2000/uL, within 4 weeks of randomization
766.0
Within 28 days prior to administration of study treatment: White blood count (WBC) > 3 x 10^9/L
90.0
White blood cell count (WBC) >= 3 x 10^9/L
132.0
